1-9 of 9
Adrienne H. Brouwers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers

Derk Jan A. de Groot, Marjolijn N. Lub-de Hooge, Tom van Meerten, Adrienne H. Brouwers, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5252–5259.
https://doi.org/10.1158/1078-0432.CCR-24-1427
Published: 02 December 2024
View articletitled, Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers
Open the PDF for Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers in another window
Journal Articles

[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M.E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A.M. van der Veldt, Anne I.J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F.A. Mulders, Otto S. Hoekstra, Gerben J.C. Zwezerijnen, Winette T.A. van der Graaf, Erik H.J.G. Aarntzen, Wim J.G. Oyen, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 592–601.
https://doi.org/10.1158/1078-0432.CCR-22-0921
Published: 01 February 2023
View articletitled, [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Open the PDF for [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Marjolijn N. Lub-de Hooge, Iris C. Kok, Adrienne H. Brouwers, Sjoerd G. Elias, Margaret T.L. Nguyen, Hong Lu, Jourik A. Gietema, Mathilde Jalving, Derk J.A. de Groot, Olga Vasiljeva, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5325–5333.
https://doi.org/10.1158/1078-0432.CCR-21-0453
Published: 01 October 2021
View articletitled, First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Open the PDF for First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody in another window
Includes: Supplementary data
Journal Articles

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok, Frans V. Suurs, Adrienne H. Brouwers, C. Willemien Menke-van der Houven van Oordt, Thijs T. Wind, Jourik A. Gietema, Carolien P. Schröder, Shekar V.K. Mahesh, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3517–3527.
https://doi.org/10.1158/1078-0432.CCR-18-2918
Published: 14 June 2019
View articletitled, 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Open the PDF for 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake in another window
Includes: Supplementary data
Journal Articles

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Frederike Bensch, Laetitia E. Lamberts, Michaël M. Smeenk, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Marlene Thomas, Wolfgang Jacob, Keelara Abiraj, Celine Adessi, Georgina Meneses-Lorente, Ian James, Martin Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6128–6137.
https://doi.org/10.1158/1078-0432.CCR-17-0311
Published: 12 October 2017
View articletitled, 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Open the PDF for 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Sue Chua, Thijs H. Oude Munnink, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Mikhail Akimov, Cristina Fernandez-Ibarra, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries, Charles Swanton, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (15): 3945–3954.
https://doi.org/10.1158/1078-0432.CCR-14-0491
Published: 31 July 2014
View articletitled, 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
Open the PDF for 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer

Adrienne H. Brouwers, Otto C. Boerman, Wim J.G. Oyen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8886.
https://doi.org/10.1158/1078-0432.CCR-05-1512
Published: 16 December 2005
View articletitled, In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer
Open the PDF for In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer in another window
Journal Articles

Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response

Adrienne H. Brouwers, Wilhelmina C.A.M. Buijs, Peter F.A. Mulders, Pieter H.M. de Mulder, Wim J.M. van den Broek, Carola Mala, Egbert Oosterwijk, Otto C. Boerman, Frans H.M. Corstens, Wim J.G. Oyen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7178s–7186s.
https://doi.org/10.1158/1078-0432.CCR-1004-0010
Published: 03 October 2005
View articletitled, Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
Open the PDF for Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response in another window
Journal Articles

Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison

Adrienne H. Brouwers, Wilhelmina C. A. M. Buijs, Egbert Oosterwijk, Otto C. Boerman, Carola Mala, Pieter H. M. De Mulder, Frans H. M. Corstens, Peter F. A. Mulders, Wim J. G. Oyen
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3953s–3960s.
Published: 01 September 2003
View articletitled, Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison
Open the PDF for Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison in another window